WP lead Dr Tina Gaarder, Oslo
A critical barrier to the enhancement of TIC management is the ability to rapidly and accurately diagnose the disease. TACTIC partners have already demonstrated the potential for VHA in this role , and will build-upon the data from WP3&4 to:
- Define VHA diagnostic criteria of ‘normal’ and ‘coagulopathic’ patients.
- Formalise the classification of TIC patient patterns.
- Map biomarker signatures to VHA profiles of coagulopathic patients.
Define VHA criteria for clinical definition of ‘normal’ and ‘coagulopathic’ coagulation.
- Determine VHA profiles associated with TIC patterns.
Provide risk stratification score for the identification and characterisation of TIC.